• Christopher Moreau, CEO of Algernon Pharmaceuticals sat down with Brieanna McCutcheon to discuss Algernon’s unique approach to the psychedelics and health care sectors
  • Algernon Pharmaceuticals is a clinical stage pharmaceutical development company that investigates safe, already approved drugs and compounds for new disease applications
  • The company is advancing several compounds including Ifenprodil and DMT
  • Algernon is closing enrollment for a 20-patient Ifenprodil study
  • Shares of Algernon Pharmaceuticals Inc. (AGN) are currently trading at $7.99

Christopher Moreau, CEO of Algernon Pharmaceuticals sat down with Brieanna McCutcheon to discuss Algernon’s approach to the psychedelics and health care sectors.

Algernon Pharmaceuticals is a clinical-stage pharmaceutical development company. Algernon investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications.

Algernon is currently advancing a number of compounds including Ifenprodil for the treatment of chronic cough and N, N-Dimethyltryptamine, or DMT, a hallucinogenic drug for stroke treatment.

Algernon is currently closing enrollment for a 20-patient Ifenprodil study in Australia and New Zealand.

Shares of Algernon Pharmaceuticals Inc. (AGN) are currently trading at $7.99.

More From The Market Online
Image description: an AI generated photo with a stethoscope

WELL Health receives C$15.3 million in funding for AI healthtech

WELL Health Technologies (TSX:WELL) locks in C$15.3 million in funding for a project to develop artificial intelligence health technology.
Theratechnologies image of a lab technician handling samples

Theratechnologies stock jumps on positive income report

Theratechnologies stock (TSX:TH) opens nearly 4 per cent higher on Wednesday on the release of its latest financial results.